Nimbus Lakshmi
About Nimbus Lakshmi
Nimbus Lakshmi is a Healthcare company based in Cambridge (United States), and was acquired by Takeda in December 2022. Therapeutics for psoriasis treatment are developed by the company. Its chief executive, as recorded, is Christophe Weber. Its focus areas include Life Sciences, Dermatology, Drugs and Psoriasis.
Company details
Therapeutics targeting psoriasis are developed by Nimbus Lakshmi, a biotechnology firm based in Cambridge, United States. The lead candidate, Deucravacitinib, functions as a tyrosine kinase 2 inhibitor. An additional IRAK4 inhibitor is pursued to address TYK2 and KRAS pathways in immune signaling. Operations focus on advancing these candidates through clinical stages in the pharmaceutical sector, with leadership provided by CEO Christophe Weber.
- Headquarters Cambridge, United States
- Stage Acquired
- SectorsHealthcare
- Acquired by Takeda (Dec 2022)
- Investors
- Acquired byTakeda
(Dec 2022)
Investors in Nimbus Lakshmi
Nimbus Lakshmi has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Takeda Pharmaceuticals is engaged in developing innovative medicines globally. | 1781 | takeda.com | Tokyo, Japan |
Investor details for Nimbus Lakshmi
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nimbus Lakshmi
1 people are tracked at Nimbus Lakshmi (1 in leadership).
| Name | Role | Group |
|---|---|---|
Christophe Weber | CEO | Leadership |
Complete people profiles for Nimbus Lakshmi
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Top companies in Dermatology
3 companies that operate in the same segment as Nimbus Lakshmi (Dermatology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Nimbus Lakshmi
Nimbus Lakshmi is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Christophe Weber is the CEO of Nimbus Lakshmi, as recorded in our data.
Therapeutics targeting psoriasis are developed by Nimbus Lakshmi, a biotechnology firm based in Cambridge, United States. The lead candidate, Deucravacitinib, functions as a tyrosine kinase 2 inhibitor. An additional IRAK4 inhibitor is pursued to address TYK2 and KRAS pathways in immune signaling. Operations focus on advancing these candidates through clinical stages in the pharmaceutical sector, with leadership provided by CEO Christophe Weber.
Nimbus Lakshmi has 1 investor. Key investors include Takeda Pharmaceuticals.
Yes. Nimbus Lakshmi was acquired by Takeda in December 2022.